Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 944Neoplasms 713Prostatic Neoplasms 498Lung Neoplasms 402Colorectal Neoplasms 363Carcinoma, Non-Small-Cell Lung 362Leukemia, Myeloid, Acute 290Pancreatic Neoplasms 239Brain Neoplasms 230Neoplasm Metastasis 225Multiple Myeloma 218Carcinoma, Hepatocellular 202Head and Neck Neoplasms 187Glioblastoma 183Precursor Cell Lymphoblastic Leukemia-Lymphoma 181Melanoma 177Ovarian Neoplasms 170Squamous Cell Carcinoma of Head and Neck 161Rectal Neoplasms 145Uterine Cervical Neoplasms 144Recurrence 143Hematologic Neoplasms 137Sarcoma 136Glioma 132Stomach Neoplasms 129Triple Negative Breast Neoplasms 127Carcinoma, Renal Cell 126Myelodysplastic Syndromes 114Colonic Neoplasms 113Esophageal Neoplasms 111

Interventions

zimberelimab 1sacituzumab govitecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Urothelial Bladder Carcinoma × 90 days × Clear all
NCT06133517 2026-03-16

PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer

Fundación para el Progreso de la Oncología en Cantabria

Phase 2 Active not recruiting
70 enrolled
Genitourinary

Urothelial Bladder Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡